Cencora (COR) News Today

Cencora, Inc. (COR) — Shares are trading higher today after a sharp selloff earlier this week. Investors are parsing mixed Q2 results: management raised FY2026 adjusted EPS guidance and authorized buybacks/dividends (supportive), but the quarter missed revenue and EPS expectations and highlighted U.S. segment softness (pressuring sentiment). Below are the main, investor-relevant headlines and links.

• Positive Sentiment: Management raised FY‑2026 adjusted EPS guidance to $17.65–$17.90 and approved a $1 billion share repurchase program — this provides capital‑return support and signals confidence in profitability. Cencora signals FY2026 EPS of 17.65-17.90 while resuming $1B share repurchases
• Positive Sentiment: Cencora announced a quarterly dividend (record May 15; $0.60 per share) and reiterated margin improvement initiatives (OneOncology integration cited as a driver). These cash returns and margin tailwinds can bolster near‑term investor confidence.
• Neutral Sentiment: Major analysts trimmed price targets but kept constructive ratings — Citigroup cut its target to $355 (still a Buy) and Robert W. Baird trimmed to $339 (Outperform). Lower targets reduce near‑term upside expectations even as analyst support remains. Citigroup price target cut Baird price target cut
• Neutral Sentiment: Earnings call transcript and slide deck are available for review — useful for investors wanting management commentary on client dynamics, GLP‑1 margin impacts and remediation steps. Q2 2026 Earnings Call Transcript
• Negative Sentiment: Q2 results missed revenue and adjusted EPS estimates — reported adjusted EPS $4.75 vs. ~$4.82 consensus and revenue ~$78.4B vs. ~$81.1B expected; management flagged U.S. Healthcare Solutions weakness (branded price cuts, lower orders from a large mail‑order client and prior customer losses). That miss triggered the earlier sharp selloff. COR Misses Q2 Earnings and Revenue Estimates
• Negative Sentiment: The stock plunged after the report (hit multi‑month/52‑week lows in intraday trading) as investors focused on near‑term revenue softness and customer mix risks, outweighing the EPS guide raise for some holders. Cencora hits 52-week low after guidance cut
• Negative Sentiment: Notable insider selling and mixed institutional repositioning were flagged in commentary — could amplify short‑term selling pressure if sentiment remains fragile. Quiver Quant summary of reactions & insider activity

Bottom line for investors: near‑term downside risk stems from the revenue miss, U.S. segment headwinds and lowered analyst targets; offsetting positives are the boosted FY EPS guide, buybacks and dividend. If you own COR, monitor customer‑mix commentary and buyback execution; traders may view the post‑selloff bounce as a risk/reward entry, while longer‑term investors should weigh execution on margin and client retention before adding exposure.